Erasca, Inc. faces a class action lawsuit alleging securities fraud for making false claims about its cancer drug ERAS-0015. The company touted the drug as "best-in-class" with superior preclinical results, but failed to disclose patent disputes and misleading comparisons. After revelations of patent infringement accusations and a patient death in clinical trials, Erasca's stock fell over 45%. Investors who bought shares between January 2025 and April 2026 may seek damages, with a lead plaintiff deadline of August 10, 2026.
SpaceX recently launched its IPO, raising $75 billion and reaching a market cap over $2.1 trillion. This major event could trigger a wave of tech IPOs from companies like Anthropic, OpenAI, Anduril, Databricks, and Stripe. Anthropic and OpenAI have f...
MYX Finance's price fell 25% to $0.1807 with a 67% increase in trading volume, indicating strong selling pressure. Despite this, 79% of top Binance traders remain long, showing bullish sentiment that contrasts with technical and derivatives data sign...
ICE Box introduces a personal document storage system designed to consolidate important household records, valuables, and digital files into one fireproof, water-resistant unit. The system includes 12 labeled folders, a 32GB USB stick for digital bac...
The Rosen Law Firm has announced an investigation and class action lawsuit on behalf of GoDaddy Inc. shareholders who may have suffered losses due to allegedly misleading business information released by the company. Investors who purchased GoDaddy s...
XM, an international online trading platform, announced improvements in technology, educational resources, and user accessibility to support global traders. The platform offers multiple trading options including MetaTrader 4 and 5, along with mobile ...
